Literature DB >> 6696743

Structural requirements of thiol compounds in the inhibition of human liver iodothyronine 5'-deiodinase.

R Harbottle, S J Richardson.   

Abstract

2-Thiouracil and a number of its alkyl derivatives are known to inhibit the enzymic 5'-deodination of thyroxine to 3,5,3'-tri-iodothyronine. The structural requirements for inhibition of iodothyronine 5'-deiodinase were investigated by using a washed postmitochondrial particulate fraction of human liver. A series of sulphur-containing derivatives of pyrimidine, pyridine, imidazole, benzene and urea, capable of existing in a thiol form, were incubated at several concentrations with the enzyme preparation in the presence of thyroxine and dithioerythritol (cofactor). The degree of inhibition by the respective compounds of the production of 3,5,3'-tri-iodothyronine was studied in relation to their structural features. The major observations were: (i) a free thiol group is essential; (ii) compounds that do not possess a polar hydrogen atom spatially configured so that it is proximal to the thiol group are poor inhibitors; (iii) aromatic characteristics in the presence of requirements (i) and (ii) lead to the expression of potent inhibitory properties; (iv) modification of potent inhibitors by the introduction of hydrophilic substituents reduces the inhibitory potency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696743      PMCID: PMC1153240          DOI: 10.1042/bj2170485

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Subcellular localization of a rat liver enzyme converting thyroxine into tri-iodothyronine and possible involvement of essential thiol groups.

Authors:  T J Visser; I Does-Tobé; R Docter; G Hennemann
Journal:  Biochem J       Date:  1976-08-01       Impact factor: 3.857

2.  EFFECT OF 5- AND 6-PROPYLTHIOURACIL ON THE METABOLISM OF L-THYROXINE IN MAN.

Authors:  J M HERSHMAN
Journal:  J Clin Endocrinol Metab       Date:  1964-02       Impact factor: 5.958

3.  Conversion of thyroxine into tri-iodothyronine by rat liver homogenate.

Authors: 
Journal:  Biochem J       Date:  1975-09       Impact factor: 3.857

4.  The reaction of thiouracil with beta-lactoglobulin sulfenyl iodide.

Authors:  L Jirousek
Journal:  Biochim Biophys Acta       Date:  1968-11-12

5.  The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man.

Authors:  C S Pittman; J B Chambers; V H Read
Journal:  J Clin Invest       Date:  1971-06       Impact factor: 14.808

6.  Sulfhydryl groups and the monodeiodination of thyroxine to triiodothyronine.

Authors:  I J Chopra
Journal:  Science       Date:  1978-02-24       Impact factor: 47.728

7.  A study of extrathyroidal conversion of thyroxine (T4) to 3,3',5-triiodothyronine (T3) in vitro.

Authors:  I J Chopra
Journal:  Endocrinology       Date:  1977-08       Impact factor: 4.736

8.  Conversion of thyroxine (T4) and triiodothyronine (T3) and the subcellular localisation of the converting enzyme.

Authors:  R D Hesch; G Brunner; H D Söling
Journal:  Clin Chim Acta       Date:  1975-03-10       Impact factor: 3.786

9.  Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man.

Authors:  D L Geffner; M Azukizawa; J M Hershman
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

10.  The mechanism of action of the thioureylene antithyroid drugs.

Authors:  A Taurog
Journal:  Endocrinology       Date:  1976-04       Impact factor: 4.736

View more
  2 in total

1.  Screening the ToxCast Phase 1 Chemical Library for Inhibition of Deiodinase Type 1 Activity.

Authors:  Michael W Hornung; Joseph J Korte; Jennifer H Olker; Jeffrey S Denny; Carsten Knutsen; Phillip C Hartig; Mary C Cardon; Sigmund J Degitz
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

2.  Phenylthiourea specifically reduces zebrafish eye size.

Authors:  Zeran Li; Devon Ptak; Liyun Zhang; Elwood K Walls; Wenxuan Zhong; Yuk Fai Leung
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.